Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC3R | P41968 | 17/20 | 0.54 |
| ▸ | MC4R | P32245 | 17/20 | 0.54 |
| ▸ | MC1R | Q01726 | 16/20 | 0.54 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5845484 | 0.96 | MC3R (0.51) | MC3RMC4RMC1RDPP4 | |
| SCHEMBL5843764 | 0.94 | MC3R (0.56) | MC3RMC4RMC1R | |
| SCHEMBL5845193 | 0.91 | MC3R (0.50) | MC3RMC4RMC1R | |
| Hydrochloric Acid SCHEMBL5843756 | 0.88 | MC3R (0.71) | MC3RMC4RMC1R | |
| SCHEMBL5845064 | 0.88 | MC3R (0.71) | MC3RMC4RMC1R | |
| SCHEMBL6334030 | 0.86 | MC4R (0.56) | MC3RMC4RMC1R | |
| SCHEMBL5845743 | 0.86 | MC4R (0.56) | MC3RMC4RMC1R | |
| SCHEMBL5845480 | 0.86 | MC4R (0.48) | MC3RMC4RMC1R | |
| Hydrochloric Acid SCHEMBL5845818 | 0.86 | MC3R (0.56) | MC3RMC4RMC1RDPP4 | |
| SCHEMBL5845167 | 0.85 | MC3R (0.47) | MC3RMC4RMC1RDPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556361-A2 | 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050010031-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2005-01-13 | — | — | US | claimed |
| WO-2004037797-A2 | 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-06 | — | — | WO | claimed |
| US-7132539-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060247224-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-11-02 | — | — | US | disclosed |
| EP-1556361-A2 | 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037797-A2 | 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010031-A1 | Melanocortin receptor ligands | MC3R, MC5R, MC1R | MC3R 1/4885MC4R 8/4885MC1R 3/4885 |
| US-20060247224-A1 | Melanocortin receptor ligands | MC3R, MC5R, MC1R | MC3R 1/4885MC4R 8/4885MC1R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.